Amyloidosis

Media

2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation

Michelle Kittleson

Watch time: 4m
HF 22: HELIOS-A: Vutrisiran in Patients with hATTR Amyloidosis

Watch time: 4m 42s
AHA 22: Results of the CRISPR-Cas9 First-in-Human Trial

Julian Gillmore

Watch time: 8m 12s
AHA 22 Late-Breaking Science Highlights With Dr Joseph Hill

Joseph A Hill

Watch time: 5m 44s
HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi

Harriette Van Spall, James L Januzzi

Watch time: 13m 32s
ESC 24: Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi

Mirvat Alasnag, Khaled Al-Shaibi

Watch time: 17m 25s
AHA 24: Nexiguran Ziclumeran for ATTR-CM

Marianna Fontana

Watch time: 5m 6s
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie

Harriette Van Spall, Mark Petrie

Watch time: 15m 26s
ESC 24: 3 Trials That Will Change My Practice

Michelle Kittleson

Watch time: 13m 47s
HFA 23: APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis

Marianna Fontana

Watch time: 3m 11s
ACC 23 Expert Consensus Decision Pathway on Cardiac Amyloidosis: Highlights

Michelle Kittleson

Watch time: 6m 19s
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies

Marianna Fontana

Watch time: 8m 1s

Articles

Amyloid Heart Disease

Yaser Nemshah

,

Alex Clavijo

,

Gyanendra Sharma

,

Citation:

US Cardiology Review 2018;12(2):113–8.

DOI:

https://doi.org/10.15420/usc.2018.5.1
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 3064
  • Downloads: Downloads 35
  • Citations: 2